Cancer Research UK logo.
SearchDonate
  • Search

A trial of SCIB1 and iSCIB1+ with immunotherapy for advanced melanoma (The Scope Study)

Overview

Cancer types:

Melanoma, Secondary cancers

Status:

Closed

Phase:

Phase 2

Details

This trial is looking at adding SCIB1 or iSCIB1+ to nivolumab and ipilimumab for melanoma. It is also looking at adding SCIB1 to pembrolizumab for melanoma.

It is for people whose melanoma has grown into surrounding tissues or spread elsewhere in the body. This is advanced melanoma.

Recruitment start: 19 August 2019

Recruitment end: 9 October 2025

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Poulam Patel

Supported by

Scancell Ltd

Last reviewed: 18 Dec 2025

CRUK internal database number: 16281

Help and support